retatrutide clinical trial south africa trials Clinical design, biomarkers and end points in metabolic and alcohol-related liver disease SAHPRA - South African Health

(2024, January 18)

The clinical trial programme for semaglutide 2.4 mg (STEP trials), which included over 4,500 participants followed for up to 68 weeks as documented in the European Public Assessment Report (EPAR), did not identify diverticulitis as a treatment-emergent adverse event occurring at rates higher than placebo

Patients with certain GIPR rs1800437 variants, for example, may show different satiety responses to the same dose schedule, which influences whether taking your injection early or late causes noticeable appetite suppression differences

Eli Lilly has introduced a new oral GLP-1 medication, Orforglipron (FoundaYO) the first of its kind in pill form